Tag Archives: streetwise reports

Target Price Lowered on Goldcorp to Reflect Updated Model

Sourced from: https://www.countingpips.com/2019/03/target-price-lowered-on-goldcorp-to-reflect-updated-model/

)

At a March 11 research note, analyst Anita Soni noted that CIBC lowered its price target on Goldcorp Inc. (G:TSX; GG:NYSE) into US$12 percent share in US$12.50 (present share price is roughly US$10.93) after adjusting its version on the major “to signify 2019 guidance, year-end outcome and technical reports. ”
Members or her of her household own securities of the following companies mentioned in the post: Not one. Members or her of her household are compensated by these companies discussed in this article: None.
2) The following firms mentioned in this post are equipping sponsors of Streetwise Reports: None. Click on here for significant disclosures about sponsor fees.
3) Comments and opinions expressed are those of the particular experts rather than of Streetwise Reports or its officers. The information provided above is for informational purposes only and isn’t a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Every reader is invited to talk to her or his individual financial pro and any action a reader takes as a result of information presented here is his or her own duty. By opening this site, each writer agrees and accepts to Streetwise Reports’ terms of usage and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports doesn’t leave specific or general investment information and the information on Streetwise Reports should not be thought of as a recommendation to purchase or sell any security. Streetwise Reports doesn’t support or recommend the company, goods, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of the families, in addition to persons interviewed for interviews and articles on the site, might have a long or short position in securities mentioned. Directors, officers, employees or associates of the immediate families are prohibited from making purchases or earnings of those securities in the open market or otherwise from the time of their meeting or the choice to compose an article until three business days following the publication of this interview or article. The foregoing prohibition does not apply to articles that in material only restate previously published company releases. As of this date of this article, officers or employees of Streetwise Reports LLC (such as members of the household) own reports of Goldcorp, a business discussed in this article.

Every CIBC World Markets Corp./ / Inc. research analyst named on the front page of the research report, or at the start of almost any subsection hereof, hereby certifies that (I) the opinions and recommendations expressed herein accurately reflect such research analyst’s private views about the business and securities which are the subject of the report and all other companies and securities discussed in this report that are covered by such research analyst and (ii) no portion of the research analyst’s compensation has been, is, or will be, either directly or indirectly, associated with the specific recommendations or opinions expressed by such research analyst in this report.

CIBC expects Goldcorp shares to become range-bound “awaiting the final outcome of the proposed acquisition by Newmont. ”
Resource: Streetwise Reports   03/14/2019
Advances analysts employed by CIBC World Markets Corp./Inc. are paid from revenues generated by various CIBC World Markets Corp./Inc. businesses, including the CIBC World Markets Investment Banking Department. Research analysts do not receive compensation based upon earnings from specific investment banking transactions. CIBC World Markets Corp./ / Inc. generally prohibits any research analyst along with any member of their family from executing trades in the securities of a business that this research analyst covers. Furthermore, CIBC World Markets Corp./ / Inc. generally prohibits any research analyst from serving as an officer, director or advisory board member of a company that such analyst covers.



In addition to 1% ownership positions in covered companies that are needed to be specifically disclosed in this report, CIBC World Markets Corp./Inc. may have a lengthy standing of less than 1% or a short position or deal as principal in the securities mentioned herein, related securities or in options, futures or other derivative instruments based thereon.

Analysts employed outside the U.S. are not registered as research analysts with FINRA. These analysts might not be connected persons of CIBC World Markets Corp. and consequently may not be subject to FINRA Rule 2241 restrictions on communications using a subject company, public looks and trading securities held by a research adviser account.
By The Gold Report

The consequence of CIBC’s new financial model on the gold miner lowered the net current value 5 percent (NPV5) by roughly 4 percent. As such, the lender trimmed its target price on Goldcorp. It does, however, keep its Neutral evaluation.
A CIBC report resisted the revisions and noticed their cumulative impact.

A second model revision included raising prices and all-in sustaining price (AISC) to $503 per oz ($503/oz) and $886/oz, respectively, up from $490/oz and $858/oz. Spurring this change, Soni suggested, were actual Q4/18 figures, 2019 guidance and recently got technical reports on Éléonore and Red Lake. CIBC’s new quotes are greater than Goldcorp’s projected ranges of 400 –500/oz for real expenses and $750–850/oz for AISC.
Recipients of the report are advised that any or all the foregoing arrangements, in addition to more specific disclosures set forth below, will sometimes give rise to possible conflicts of interest.

Analyst Certification:
In one, the analyst uttered, CIBC lowered its estimated 2019 total production to 2.279 million oz (2.279 Moz) from 2.324 Moz because of Goldcorp planning to lower output in Cerro Negro, Musselwhite and Porcupine. CIBC’s corrected figure nevertheless falls over the miner’therefore advice of 2.2–2.4 Moz of production in 2019.
Third, CIBC raised its 2019 capex quote on Goldcorp, to $936 million in $803 million to reflect increases at Cerro Negro and Peñasquito, Soni clarified. Unlike the previous, the newest dollar number falls over Goldcorp’s advice of $865–975 million.

Disclosures out of CIBC, Goldcorp Inc., March 11, 2019
Soni noted CIBC made three modifications to its standalone version of Goldcorp and explained what they had been.
CIBC World Markets Corp., CIBC World Markets Inc., and their affiliates, in the aggregate, beneficially own1percent or even more of a class of equity securities issued by Goldcorp Inc..

New Results from Portugal Project Suggest Presence of ‘Robust Mineralizing Event’

Sourced from: https://www.countingpips.com/2019/03/new-results-from-portugal-project-suggest-presence-of-robust-mineralizing-event/

She or members of her household own securities of the following companies mentioned in the post: None. Members or her of her household are paid by these companies discussed in this article: None.
Two ) The following businesses mentioned in this article are billboard sponsors of Streetwise Reports: Avrupa Minerals. Click on here for significant disclosures about sponsor fees.
3) Opinions and opinions expressed are those of the particular experts rather than of Streetwise Reports or its officers. The information supplied above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article doesn’t constitute investment advice. Each reader is invited to talk to his or her respective financial professional and any action a reader takes as a result of information presented here’s his or her own responsibility. By opening this page, every reader accepts and agrees to Streetwise Reports’ terms of use and total authorized disclaimer. This article isn’t a solicitation for investment. Streetwise Reports doesn’t leave specific or general investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not support or recommend the business, products, services or securities of any business mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of the families, in addition to persons interviewed for interviews and articles on the site, may have a long or short position in securities mentioned. Employees, officers, employees or associates of their immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of the interview or the choice to compose an article until three business days after the publication of this interview or article. The foregoing prohibition doesn’t apply to articles that in substance simply restate previously published company releases. At this date of this guide, officers or employees of Streetwise Reports LLC (such as members of their household) own shares of Avrupa Minerals, a company discussed in this report.

By The Gold Report

Avrupa Minerals Ltd. (AVU:TSX.V; AVPMF:OTC; 8AM:FSE) announced within an news release that the current drill results from the Sesmarias project in southern Portugal demonstrate significant added potential to upgrade the famous mineralized system .

Disclosure:

)

Ultimately, results affirmed the high-grade 2 lens is a “fault-bounded fragment of massive sulphide mineralization”; its source has not yet been determined.

This junior explorer may use these data to ascertain its next drill aims at the asset.


Resource: Streetwise Reports   03/12/2019
Hole SES028, beneath the 8 lens, hit the border of a substantial feeder zone stockwork that revealed anomalous gold, silver, copper, zinc and lead mineralization throughout its whole length, from 373.4m to 460.8m in depth. This additional “supports that the Sesmarias program is a strong mineralizing occasion,” President and CEO Paul Kuhn stated in the launch.
Subscribe to our FREE newsletter : www.streetwisereports.com/get-news
Read what other experts are saying about:
The drill program, which consisted of six holes in 2,498 meters (2,498m), explored new locations and “affirmed a fresh exploration and mineralization version for the district,” ” the discharge noted.
The findings contained intersection of mineralization in orbit SES026 consisting of 28.95m of 0.48% aluminum and 0.77 gram per ton stone. This hole also extended the 10 lens into the north through 300 meters, taking its measurements to 600m extended by 300m wide by 25m thick. SES026 also identified possible new mineralization over the 10 lens, and that both holes SES027 and SES029 additionally encoded.

Small-Cap Energy Firm a ‘Strong Buy’

Sourced from: https://www.countingpips.com/2019/03/small-cap-energy-firm-a-strong-buy/

Subscribe to our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
Source: Clive Maund for Streetwise Reports   03/12/2019
The above represents the opinion and analysis of Mr Maund, based on data available to himat the time of writing. Mr. Maund’s remarks are his very own, and are not a recommendation or an offer to purchase or sell securities. Mr. Maund is an independent analyst who receives no compensation of any sort from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a professional investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any sort of a transaction with financial ramifications. Even though a skilled and skilled stock market analyst, Clive Maund isn’t a Registered Securities Advisor. Therefore Mr. Maund’s remarks available on the sector and shares can only be construed as a solicitation to purchase and sell securities when they are subject to the prior consent and endorsement of a Registered Securities Advisor operating in compliance with the right regulations in your field of jurisdiction.

)

So we can expect investor attention to build ahead of the conference call, and whether the phone gets investors excited we might even see a spike in the share price immediately following (which we of course would sell into). Our 3-month graph below shows that Torchlight is nicely set up for another run that may easily take it nicely beyond the February peak–it’s merely above a very powerful support amount with additional support in the rising 50-day moving average coming into play, and we have only seen a bullish moving average cross, as well as the sooner overbought condition that prompted us to consider profits has unwound.

Technical analyst Clive Maund charts this small-cap energy firm and explains why he sees it as a strong buy.
1) Clive Maund: I, or members of the immediate household or family, own stocks of these companies mentioned in this post: Not one. I am, or members of my immediate family or family are, paid by the following companies discussed in this post: None. My firm has a financial relationship with these companies mentioned in this article: Not. CliveMaund.com disclosures below. I determined which firms would be contained within this article based on my research and comprehension of the industry.
Two ) The following companies discussed in this article are billboard sponsors of Streetwise Reports: Torchlight Energy. Click here for significant disclosures about host fees. At this date of this article, an affiliate Streetwise Reports comes with a consulting relationship with Torchlight Energy. Please click here to learn more.
3) Statements and opinions expressed are the opinions of the author rather than Streetwise Reports or its officers. The writer is fully responsible to the validity of the statements. The author was not compensated by Streetwise Reports with this article. Streetwise Reports wasn’t paid by the author to print or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to purchase or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic connections with, companies that they write about. Streetwise Reports depends upon the authors to accurately provide this info along with Streetwise Reports without a means of verifying its accuracy.
4) This article doesn’t constitute investment advice. Every reader is encouraged to talk to their respective financial pro and any actions a reader chooses as a result of information presented here’s his or her own responsibility. By opening this site, every writer agrees and accepts to Streetwise Reports’ terms of use and total lawful disclaimer. This report isn’t a solicitation for investment. Streetwise Reports doesn’t leave general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports doesn’t support or recommend the business, products, services or securities of any business mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of the families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or associates of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of their meeting or the choice to compose a post until three business days following the publication of this interview or post. The foregoing prohibition does not apply to articles that in material just restate previously printed company releases. At this date of this guide, officers or personnel of Streetwise Reports LLC (including members of the family ) own reports of Torchlight Energy, a company mentioned in this article.

Torchlight Energy site .

Torchlight is therefore rated a strong buy again here, and people who sold part of the holdings before near into the February peak as suggested can buy back here.

Charts offered by the author.

Read what other pros are saying about:

Marijuana: Up in Smoke

Sourced from: https://www.countingpips.com/2019/03/marijuana-up-in-smoke/

Charts and pictures offered by the writer.
Canopy reported excellent Q3 effects on Feb. 14 in Canadian dollars. It was the first complete quarter of recreational sales in Canada and revenue increased to $83 million, up 256 percent from the previous quarter. The business sold 10,102 kilograms of cannabis and petroleum equivalent. The business is still losing money and also my first consideration was that the fantastic quarter was a result of inventory drawdown in expectation of legalization. But, stock at Dec. 31 was $184,961,000up from $150,406,000 reported Sept. 30, so was great to see.

Canopy has done a lot of diversification out Canada. In mid-January it created a $150 million investment to come up with large-scale hemp manufacturing in New York state.
Products

In the end of January Greg Mills, previously head of RBC Capital Markets’ global equities, combined the RISE board of supervisors. According to the statement, “Mills combined RBC at 1998 as part of equity trading, also in 2005 has been promoted to head of global equities and served in that position till 2018. Mills’ important responsibilities included business planning, risk management, international gain and loss, customer relations employee mediation and equity analysis. ”
Allow ’s consider several prior stocks that I remarked on and a couple new ones.
A company that has something in common with Canopy and Tilray is currently Valens Groworks. They’re recognized as a leader in this regard and also have agreements with many big cannabis manufacturers.

Volumes are mild, so it might take some patience to buy underneath US$0.25.
Valens won’t post the large earnings of selling a lot of consumer end product (flower) but will be capturing the margins on flower to petroleum, which are rather large. Its input costs are a lot lower and Valens is likely to be much more profitable than the big LPs.

On Dec. 13, 2018, Valens announced a bargain to provide multiyear extraction services to get Canopy Growth, and on Feb. 26, 2019, declared a multiyear deal using Tilray to get at least 15,000 kilograms (15,000 kg) of dried cannabis per year.

This graphic is a slide in the Valens presentation.
Costing $40 million cash from the $280 million market cap and the stock is trading at only five times projected 2019 earnings, quite cheap compared to many.

Both the Canadian and U.S. bud indicators had a very substantial dip following my Oct. 4 report and have now bounced up. The Canadian indicator appeared in January 2018 and had a bear market rally into the October 2018 high. The present rally looks like another tolerate rally.

On Feb. 7, Canopy announced it is increasing its fascination with Canopy Rivers from 26.5% to 27.3%. Canopy Rivers works collaboratively with Canopy Growth to spot tactical counterparties seeking fiscal and/or operating support and affiliation with the Canopy Growth group of businesses. This helps to create the Canopy brand and also provides diversification out Canada.

Ron Struthers founded Struthers’ Resource Stock Report 23 Years Back. The report covers senior and junior companies with ample trading liquidity. He began his Millennium Index of money stocks at 2003 – $1,000 spent then was worth $4,000 end of 2014 and the index returned 26.8% in 2016. He retired from IBM after 30 years in customer service, systems and business analyst, and also creating his own charting software.

In its statement on the farm invoice , the company mentioned “RISE’s lifestyle merchandise brands, Life Bloom Organics and Karezza, feature hemp-extracted cannabidiol oil. Using industrial hemp–the identical material legalized by the 2019 Farm Bill–has enabled their products to be available to most U.S. customers, with shipping offered to all 50 states. Using industrial hemp in their formulations also suggests that the RISE Life Science brands will gain from ongoing and much greater accessibility to standard raw plant materials. The farm bill helps support hemp farmers by offering them with agricultural benefits and support not before available. ”

Valens Farms’ B.C. Growing
With decades of success in broadcasting, publishing, online along with merchandising, Martha Stewart has strongly cemented herself as one of the very well-respected businesswomen from the United States. ”
I think RISE is put very well in this new cannabis market and the stock prices has not reflected that yet. There’s more trading on the side so I reveal that graph. There is an uptrend in position as well as the pullback from recent highs gives a much better entry cost. It will likely take costs over $0.40 for bandwidth to enhance.

If you talk at any pothead, they will tell you the cannabis can heal anything and is good for everything, such as improved sex. RISE does not have any cannabis production but has established its unique brand of wellness products, including a few for sexual enhancement. They say “gender sells,” therefore this might be a nice benefit for RISE.
It now reminds me of Canada’s variant of marijuana legalization. Maybe the legislators should have been when they made this policy change, because they sure screwed it up. You will find excess rules and laws around growing bud. However the greatest mistake, at least up to now, is a very poor retail market for recreational usage. Ontario is the largest province in Canada, with approximately 40% of the populace, and is now putting plans in place to open the very first 25 bud stores. It was a lottery and several of the winners don’t have very little retail or business experience.


The stock transactions more volume on the Canadian side under symbol VGW, but this US$ price graph shows a higher close, and trading over US$2.25 in February, thus a technical breakout. The recent pullback is an adequate entry level, and it has established some support about $1.80. A closing above $2.45 will be quite positive.

The inventory has dropped 50% since my warning that it had been way too expensive in ancient October 2018, and I still can’t locate a great reason to possess it. There is simply too much buzz on this inventory and even about the company’s website it’s tough to sift through and find the actual news. It is making some decent moves however, taking advantage of its high share worth and money.

  • Is shelf stable for over 180 days (not proven anywhere else);
  • has anti cannabis taste, color or odor;
  • offers effective, consistent dosing;
  • has lower dosage because of a rise in bio-availability once absorbed;
  • has a quicker onset and offset, which makes it the more healthy and more trusted edible choice.

This was a wonderful bargain for Valens since its own zero cash outlay, together with Kosha contributing 100% of property, construction and equipment expenses. All challenging assets will be split 50/50 between Kosha and Valens, thus supplying $37.5 million of net assets to Valens’ balance sheet with no cash outlay or liability incurred. Valens and Kosha will split profits to a 50/50 basis following cost recovery from Kosha. Valens Farms is anticipating Phase 1 production up to 56,000 kg a year of premium monocrop cannabis, primarily for extraction purposes. This will be exclusively extracted by Valens and made into Valens branded goods.

Markets change direction with consensus beliefs, which might change at any time and without notice. The author/publisher of the book has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author’so control, no representation or warranty is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions will not be made the basis for any claim, demand or cause of action. Due to the ever-changing character of information & statistics the author/publisher strongly motivates the reader to speak directly with the company or using their private investment advisor to obtain up to date information. Past results are not necessarily indicative of future results. The author/publisher may or may not have a position in the securities and/or choices relating thereto, & may make purchases or earnings of these securities relating thereto from time to time from the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to purchase or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter isn’t a qualified financial adviser & is not acting as such in this book.
Many have compared the magnitude of the marijuana market to this beer and wine or alcohol industry. Are you laughing yet? I expect that when CBD-infused drinks are legalized after this year, they simply put them on the shelves of the LCBO, but this would be too straightforward and cost-effective.

The biggest joke is the low number. I am able to drive approximately 20 minutes down the highway from where I reside to the First Nations book, where there are more than 50 outlets running and they’re all busy. Since legalization, users are not worried about hauling marijuana they buy on the book. Many are driving one or two hours to receive it. The item, for the most part, comes from the black market. Just 1 socket, Legacy 420, asserts it has revenue of approximately $20 million annually, which was before legalization.

From The Life Science Report
Valens will not require large grow centers and will gain from the much higher margins on cannabis petroleum. Its proprietary extraction process is boasted as the very best and most efficient in the marketplace. Investors are able to attest to the using the ISO 17025 certification, the Thermo Fisher award and supply deals with Canopy Growth, Tilray and several more.
It is also worth noting the Valens Labs includes a Health Canada Dealers license, is the very first ISO 17025 accredited laboratory in Canada for a cannabis matrix also has been called a “Center of Excellence in Plant According Science” from Thermo Fischer Scientific.


Valens Groworks Corp. (VGW:CSE; MYMSF:OTC ): 93.2 million (93.2M) shares out; market cap CA$280M; money available $41M


Valens has declared numerous similar deals together with Organigram, Sundial Growers, Harvest One and, most recently, on March 11, using Green Organic Dutchman, that will provide Valens with an annual minimum of 30,000 kg in the first year and 50,000 kg in two.

The statement goes on to state, “Delivery of product to Solcanna is subject to regulatory acceptance from COFEPRIS, the Mexican Secretariat of Health’s agency responsible for the regulation of a variety of meals – and medical products in Mexico, to which application has been made. ” Mexico is a huge market with a population of more than 123 million individuals along with the government is shifting toward legalization. The government controls the house, so no significant setbacks are anticipated with the legislation.

  • A longer shelf life in comparison to this flower;
  • aging flower can be bought at a discount;
  • numerous applications as shown above;
  • higher margins on oils and resins.

The stock is still too pricey and the graph shows it could be on the brink of a technical break down. The stock price is just above a fantastic service level at $65. A near at $64 or lower could be a terrible sign, without a lot of support until it drops to around the $25 area. That’s where I expect that the stock is led and the March 18 earnings report may be the catalyst to make it started.


I have no doubt Canopy is going to be a pioneer and among the greatest brands in the cannabis space, but investors are paying the price for this. At the current yearly sales run rate and subtracting $4 billion cash from the market cap, the stock is currently trading around 50 times earnings. This is extremely expensive, but is frequently true with higher growth stocks where shareholders are pricing the stock on considerably higher future earnings and earnings. When there is a whiff of diminished growth, the stock will sell off hard. That is the risk before and about the upcoming quarterly report, as I feel it will be quite tough for Canopy to record triple-digit expansion over the last quarter.

  • A equity interest in Headset, a real life data and analytics firm;
  • Financing of Greenhouse Juice Company, a health and wellness beverage firm;
  • Growing its possession in Canapar, an Italy-based hemp production and processing platform capitalizing on the fast expanding European CBD (cannabidiol) marketplace.

Resource: Ron Struthers for Streetwise Reports   03/13/2019
According to the company release, at the uk, Canopy formed Spectrum Biomedical U.K., a new company dedicated to providing access to cannabis-based medicinal products into United Kingdom patients with severe unmet medical need. In addition to enlarging its medicinal cannabis surgeries in the uk, Canopy Growth’s Torun-based group, Spectrum Cannabis Polska in Poland, successfully completed its very first import of medical cannabis after finishing a rigorous regulatory approval process to have the product evaluated and accepted for sale.

Sector specialist Ron Struthers takes a peek at a range of cannabis businesses, including one firm that’s gone from a top to a downer, a business leader, and a company that promotes CBDs as good for sex.

Tilray will report Q4 and year-end earnings on March 18. Its Q3 results, reported Nov. 13, 2018, came in at US$10.0 million in earnings and it had cash of $104 million. In a $40 million earnings annual price rate, the stock is trading in 150 times annual earnings, which is about three times the amount of Canopy utilizing this comparable.

Life Bloom Organics’ proprietary Nano hemp extract oral sprays are seen at natural health food markets, including chiropractic offices, specialty retailers and medical dispensaries at Southern California, in addition to online.

Disclosure:

RISE simply began sales in Southern California from June/July, therefore its last financials only reflect about one month of earnings, which was CA$141,783. The company has only increased CA$5.5 million and have expanded into Mexico. We Will Have to see at least a couple quarters of earnings to get an idea just how its products are all moving
In the launch, Tilray states, “Since the owner of more than 50 manufacturers, ABG builds value by partnering with an expansive community of best-in-class manufacturers, operators and retailers. With a worldwide retail footprint of over 100,000 points available and over 4,500 branded freestanding shops and shop-in-shops, ABG’s portfolio creates about US$9 billion in retail sales each year. ”
According to the company, Canopy Rivers has recently expanded its portfolio by creating several innovative investments at the cannabis market worldwide, including:
I feel the Karezza product line differentiates RISE from most or all competitors. On July 12, 2018, RISE acquired Cultivate Kind. “This additional significant in-market expertise, provides instant earnings to the company and brings U.S. distribution capabilities in-house. Cultivate Kind was born from the conventional CPG service planet, and attracts over 30 decades of consumer marketing experience and brand launching approach into the RISE portfolio. For any start up with goods, marketing expertise is indispensable. ”

On March 3 Tilray declared its wholly owned subsidiary, “Tilray Portugal Unipessoal Lda (Tilray Portugal) has completed a successful crop of health cannabis in the Business ’s European Union (EU) Campus in Portugal. ”

With inflated prices, bans on edibles, heavy regulation of cultivators and limitations on private imports, customers continue dialing up their friendly local dealer to prevent all that. The Ontario legal bud market will require many years to gain significant ground on the black market. I believe it’s essential for investors to focus on companies that are growing or concentrated outside of Canada, are establishing brands and are not affected by the constraints in the Canadian retail market. Additionally, this is a follow up in my Oct. 4 account on the industry, where I cautioned that overinflated stocks had been due for a correction.
Tarulino’so called SōRSE emulsion technology encircles oils, changing the whole solution to water-compatible forms. All of this indicates that you can add cannabis to goods, such as beverages, without that “bud ” taste or odor. The Item also:
To help build its manufacturer, on Jan. 15 Tilray declared it has signed a long-term revenue sharing agreement to market and distribute a portfolio of consumer cannabis products in Actual Brands Group’s (ABG’s) brand portfolio in jurisdictions where regulations allow.


Canopy sold 10,102 kg of cannabis equivalent in the latest quarter, which might be 40,408 kg annually. Valens can process 250,000 kg per year, and just its bargain with Green Organic Dutchman, also Tilray is currently at 45,000 kg at the first year. In essence Valens will be processing and promoting more kilograms of cannabis equal than a variety of the major producers combined.
On Feb. 28 the firm shut the purchase of both Manitoba Harvest. “Founded in 1998, Manitoba Harvest is the planet ’s biggest hemp food maker and a leader in the organic foods industry. It produces, markets, markets and distributes a broad-based portfolio of hemp-based customer products, that are sold in over 16,000 shops at leading retailers across the U.S. and Canada. ”
(c) Copyright 2019, Struther’s Resource Stock Report



Sign up for our FREE newsletter in: www.streetwisereports.com/get-news

Tilray is authorized to generate medial cannabis in Chile and via its Tilray Latin America subsidiary may import and distribute products in Chile and Brazil. Tilray currently includes medical cannabis products in 12 countries through subsidiaries in Australia and New Zealand, Canada Germany and Portugal, along with Latin America.

1) Ron Struthers: Ipersonally, or members of my immediate family or family, own shares of the following companies discussed in this article: Valens Groworks and Rise Life Science. I am, or members of my immediate family or family are, compensated by the following companies discussed in this article: Not one. My company currently has a financial connection with the following companies mentioned in this post: Valens Groworks and Rise Life Science are entrepreneurs at playstocks.net. Additional disclosures below. I decided which companies would be included in this article based on my research and comprehension of the industry.
Two ) The following firms discussed in this article are sponsors of Streetwise Reviews: None. Click here for significant disclosures about host fees.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible to the validity of their statements. The author was not paid by Streetwise Reports to this report. Streetwise Reports wasn’t covered by the writer to publish or syndicate this report. The information supplied above is for informational purposes only and isn’t a recommendation to purchase or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or financial relationships with, companies that they write about. Streetwise Reports depends upon the authors to accurately provide this info and Streetwise Reports has no means of verifying its accuracy.
4) This article doesn’t constitute investment advice. Each reader is encouraged to consult with his or her respective financial professional and any action a reader takes as a result of information presented here is his or her own duty. By opening this page, every reader agrees and accepts to Streetwise Reports’ terms of usage and full authorized disclaimer. This article is not a solicitation for investment. Streetwise Reports doesn’t render general or specific investment advice and the advice on Streetwise Reports should not be regarded as a recommendation to purchase or sell any security. Streetwise Reports doesn’t support or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. Directors, officers, employees or members of their immediate families are prohibited from making purchases or earnings of these securities in the open market or otherwise from the time of the meeting or the choice to write a post prior to three business days following the publication of this interview or post. The foregoing prohibition doesn’t apply to articles that in material only restate previously published firm releases.

This is a 1978 stoner comedy that received mixed to negative reviews at the time. Nonetheless it had been a victory and is now regarded as a classic. As I remember it was about a couple of bumbling stoners that could not do much right and only a bit more in order that they were stoned.

There are many Benefits to a focus on oils and resins, for example:

This chart is at US$ price and that I see heavy resistance at the $50 to $55 area, which the stock has already tested in this rally. I see some service around $42 and robust support around $30. I see an excessive amount of risk to be long now, and when you are, I’d look to exit on a rally for $49 plus a stop/loss at $42.
Oil usage has grown at faster speeds than blossom usage since shortly after recreational legalization. You will find this is the case in Colorado, Washington and other lawful states. Also notice that Canopy reported oils at 33 percent of earnings, up from 23% in precisely the exact identical period this past year, which further attests to this.

By contrast the U.S. bud index produced a brand new bull market high in October 2018. The jury remains out on if the indicator can produce new highs. Provided that the index holds above the 105–110 area all is good, however a drop below that level could signal a substantial correction. The moves in the two indexes tend to be volatile, so moving over 20 percent in either direction.

RISE Life Science Corp. (RLSC:CSE) is quite interesting and a hidden gem

In ancient February RISE chose Solcanna SA de CV to act as a distributor of its Life Bloom Organics new cannabidiol-based health and health products in Mexico. According to the statement, “The initial purchase order executed with Solcanna will visit Life Bloom Organics’ wellness formulation originally placed in 3 primary Mexican markets: Mexico City, Guadalajara and Monterrey. . .Solcanna and RISE have proposed this launch in the Mexican market with the first order of about $350,000 to put merchandise at retailers in Mexico City, Guadalajara and Monterrey. The expectation will be for recurring orders to be placed, other Mexican markets to be launched, and additional products to be added to RISE’s Mexican portfolio. ”

An obvious way it’s possible to verify the higher margins is considering some of the LPs recent financials which are selling oils. All of them claim greater dollar values per gram marketed, and attribute that increase to greater ratios of oil and concentrate sales.
Valens is already positioned as well or better than anyone for the beverage marketplace in 2019. Its multiyear deal with Tarukino Holdings provides Valens accessibility to Tarukino’s proprietary emulsion technologies , which transforms cannabis into a water-soluble form for drinks while hammering any cannabis taste. Valens also has the distribution rights in Canada for Tarukino’s hot Happy Apple beverage, Washington State’s #1 selling cannabis infused drink three years in a row, and also Pearl20, that may be employed to mix drinks and edibles.

Analyst: Biotech to Have ‘Eventful Year’ with Data Readouts in Three Indications

Sourced from: https://www.countingpips.com/2019/03/analyst-biotech-to-have-eventful-year-with-data-readouts-in-three-indications/

Also in the report, Arce temporarily outlined DURECT’s Q4/18 financials, suggesting revenue during the quarter was $3.6 million. At 2018, the company had $34.5 million in cash and cash equivalents, along with $20.5 million of money from a term loan.

Part A registration of average AH patients for your 90 mg dose continues. Both components could advance to the final 150 mg dose if the dose escalation committee decides the safety and pharmacokinetic profiles are adequate.

Psoriasis is your second sign for which DUR-928 data will be forthcoming. DURECT has scheduled enrollment for the Stage 2a proof-of-concept trial of topical DUR-928 for mild to moderate plaque psoriasis to begin at the end of the month. This 20-patient study will include four months of therapy, then a follow-up interval of exactly the identical duration.
One of those signs is alcoholic hepatitis (AH), which will be “emerging as a top priority sign for DUR-928,” mentioned Arce. Results later this year may come from a Stage 2a open label, multicenter dose escalation research now in progress.
)

None of those study analysts or the researcher’s household has a financial interest in the securities of DURECT Corporation (including, without limitation, any option, right, justify, future, long or short position).


Disclosure:
At February 28, 2019 neither the Company nor its affiliates beneficially own 1% or more of any class of common equity securities of DURECT Corporation.

Members or her of her household own securities of these businesses mentioned in the article: Not one. Members or her of her family are paid by these companies discussed in this article: Not one.
Two ) The following firms discussed in this post are equipping sponsors of Streetwise Reports: DURECT Corp.. Click on here for significant disclosures about sponsor fees.
3) Opinions and opinions expressed are those of their specific experts rather than of Streetwise Reviews or its officers. The information supplied above is for informational purposes only and is not a recommendation to purchase or sell any security.
4) The content does not constitute investment advice. Every reader is invited to talk to her or his respective financial professional and any action a reader takes as a result of information presented here is their own duty. By opening this site, every reader agrees and accepts to Streetwise Reports’ terms of use and complete legal disclaimer. This article isn’t a solicitation for investment. Streetwise Reports does not leave general or specific investment advice and the advice on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, goods, services or securities of any business mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of the families, as well as persons interviewed for interviews and articles on the site, might have a long or short position in securities mentioned. Employees, officers, employees or members of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of their interview or the decision to compose an article until three business days after the publication of the interview or article. The foregoing prohibition doesn’t apply to articles that in substance only restate previously published firm releases.

Disclosures out of H.C. Wainwright & Co., DURECT Corporation, Earnings Update, March 8, 2019

From The Life Science Report
The research analyst primarily responsible for preparation of this report doesn’t receive compensation that’s based upon any specific investment banking services or trade but is paid based on factors such as total revenue and profitability of the Business, a significant portion of which comes from investment banking solutions.
The most recent news related to the study is from March 7, even when DURECT declared it had progressed the study to Part B, which is for severe AH patients in the 90 mg dose cohort. “The company decided to move forward in light of the “positive benefits in both moderate and severe AH patients who were awarded the 30 mg doses along with the rapid pace of enrollment in Section B, also ” the analyst wrote.
Neither the researcher nor the Firm has some material conflict of interest in of which the researcher knows or has reason to be aware in the time of publication of the study report.

I, Ed Arce and Thomas Yip, cautioned that 1) all of the viewpoints expressed in this report accurately reflect my personal views concerning any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or would be directly or indirectly linked to the particular recommendation or views expressed in this research report; and 3) neither myself nor any members of my family is an officer, director or advisory board member of these companies.

Source: Streetwise Reviews   03/12/2019
This California company anticipates results from clinical trials in liver disease and psoriasis at 2019.
Read what other pros are saying :

Newly Identified Veins at Mexico Project ‘Highlight Exploration Upside on Multiple Fronts’

Sourced from: https://www.countingpips.com/2019/03/newly-identified-veins-at-mexico-project-highlight-exploration-upside-on-multiple-fronts/

Resource: Streetwise Reports   03/11/2019

The second recently found vein, the Pre-Anticipada, is situated about 50–100m further into the hanging wall in the subparallel Anticipada vein, MacKenzie described. Pre-Anticipada was intersected by holes targeting the Valdecanas vein Deep zone. Highlight assays in the brand new strand comprised 472 g per ton (472 g/t) silver (Ag) over 3.2m, 768 g/t Ag over 1.80m and 1,256 g/t Ag over 1m.

)


Read what other experts are saying :
Especially, one of the newly identified veins, the Venadas, with its own inland orientation, sits involving runs crosswise into the northwest-traversing Valdecanas and Juanicipio veins. MacKenzie emphasized that “the minimal reported foundation metal grades and vein style/elevation comparisons to that of the Valdecanas vein imply that drilling so far has only just tested the surface of a potentially more expansive mineral system to thickness. ”

By The Gold Report

Canaccord Genuity or one or more of its affiliated companies intend to seek or hope to receive compensation for Investment

Sign up for our FREE newsletter in: www.streetwisereports.com/get-news

1) Doresa Banning compiled this article for Streetwise Reports LLC and supplies solutions to Streetwise Reports as an independent contractor. Members or her of her family own securities of these companies mentioned in the post: Not one. Members or her of her family are compensated by the following companies mentioned in this article: Not one.
2) The following companies discussed in this post are equipping sponsors of Streetwise Reviews: MAG Silver. Click on here for important disclosures about host fees.
3) Opinions and opinions expressed are those of their particular experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and isn’t a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is invited to talk to their respective financial professional and any action a reader chooses as a result of information presented here is their own duty. By opening this page, each writer agrees and accepts to Streetwise Reports’ terms of usage and complete legal disclaimer. This report isn’t a solicitation for investment. Streetwise Reports doesn’t render general or specific investment advice and the advice on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not support or recommend the company, products, services or securities of any company mentioned on Streetwise Reports. Employees, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or from the time of their interview or the decision to compose a post prior to three business days following the publication of the interview or post. The foregoing prohibition does not apply to articles that in material just restate previously printed firm releases.

A Canaccord Genuity report reviewed and reviewed such drill results and their consequences.
Up-to-date disclosures might be gotten at this website.
In its latest drilling of 48 holes covering 46,060 meters (46,060m), the firm, generally, discovered two mineralized veins and also extended existing mineralization in the huge land in Mexico.
Drilling continues at Juanicipio, together with one directional rig committed now to the Valdecanas vein and two traditional rigs centered on there. The next major catalyst for the stock, however, MacKenzie indicated, is a formal Juanicipio structure conclusion by MAG’s joint venture partner, Fresnillo.
Providers from MAG Silver Corp. from the subsequent three months.

As far as mineralization expansion, stepout drilling in Valdecanas’ Deep East along with Deep West zones expanded high-grade mineralization to depth, relayed MacKenzie. Notable intercepts comprised 1,297 g/t silver equal (Ag eq) over 6m, 637 g/t Ag eq over 13m along with 535 g/t Ag eq over 10m. “The higher precious metal ranges detected at depth within the Deep zone are thought to be a later overprint and also the product of a stacked/fluctuating boiling horizon,” he included.

Explorer Hits New Gold-Bearing Veins in Single Zone at Red Lake Project

Sourced from: https://www.countingpips.com/2019/03/explorer-hits-new-gold-bearing-veins-in-single-zone-at-red-lake-project/

All the five holes drilled intersected gold mineralization. Highlight assays included 31.4 g per bunch (31.4 g/t) gold above 0.7m at a 2.7m period of 8.7 g/t gold at a 64m vertical depth.
Cumulatively, these results reveal “the extensive footprint of gold mineralization in Dixie and the obvious importance of big D2 fold axes as regional gold controllers,” President and CEO Chris Taylor stated in the release.
Subscribe to our FREE newsletter in: www.streetwisereports.com/get-news

See what other pros are saying about:
This Canadian company aims to ascertain whether they’re zone extensions or gold discoveries.
1) Doresa Banning compiled this post for Streetwise Reports LLC and supplies solutions to Streetwise Reports as an independent contractor. She or members of her family own securities of these firms mentioned in the article: Not one. She or members of her family are compensated by the following companies mentioned in this article: None.
2) The following firms discussed in this post are equipping sponsors of Streetwise Reports: Great Bear Resources. Click on here for significant disclosures about sponsor fees.
3) Opinions and opinions expressed are those of the particular experts rather than of Streetwise Reviews or its officers. The information provided above is for informational purposes only and isn’t a recommendation to buy or sell any security.
4) The content does not constitute investment advice. Each reader is encouraged to consult with their individual financial pro and any actions a reader takes as a result of information presented here is his or her own responsibility. By opening this site, every reader agrees and accepts to Streetwise Reports’ terms of usage and total lawful disclaimer. This report is not a solicitation for investment. Streetwise Reports does not leave general or specific investment information and the information on Streetwise Reports should not be thought of as a recommendation to purchase or sell any security. Streetwise Reports doesn’t support or recommend the company, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or associates of the families, in addition to persons interviewed for articles and interviews on the website, may have a long or short position in securities mentioned. Employees, officers, employees or associates of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or from the time of their interview or the decision to compose an article prior to three business days after the publication of this interview or article. The foregoing prohibition doesn’t apply to posts that in substance just restate previously published company releases.

In other news, Great Bear recently obtained “low-cost, royalty-free property” that matches its existing acreage from Ontario’s Red Lake District. The company intends to map and explore this land this summer.

Coverage Initiated on Cancer Vaccine Firm

Sourced from: https://www.countingpips.com/2019/03/coverage-initiated-on-cancer-vaccine-firm/

Neither the research analyst nor the Firm has some material conflict of interest in of which the researcher knows or has

The Business does not make a market in Gritstone Oncology, Inc. and Advaxis, Inc. as of the date of this research report.


An H.C. Wainwright & Co. report clarified the reasons for its “bullish view” with this California-based life sciences company.
The Firm or its affiliates did not receive compensation against Gritstone Oncology, Inc. and Advaxis, Inc. for investment banking


Reason to know in the time of publication of the study.

( Companies Mentioned: GRTS:NASDAQ,

The analyst pointed out the Gritstone’s August 2018 deal with bluebird, “clearly one of the greatest cancer cell therapy players,” validates Gritstone’s technologies. The two companies are working with the EDGE AI platform to identify novel tumor goals for cell-based remedies.

Services within twelve months before, but will seek reimbursement from the companies mentioned in this record for investment
banking solutions within three weeks after publication of the research report.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her own securities of the following firms mentioned in the post: None. Members or her of her family are compensated by the following companies discussed in this article: Not one.
Two ) The following firms mentioned in this post are equipping sponsors of Streetwise Reports: None. Click on here for important disclosures about sponsor fees.
3) Opinions and opinions expressed are those of the particular experts rather than of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to purchase or sell any security.
4) This article does not constitute investment advice. Each reader is invited to consult with her or his respective financial pro and any actions a reader takes as a result of information presented here is their own responsibility. By opening this site, each reader accepts and agrees to Streetwise Reports’ terms of use and total authorized disclaimer. This guide isn’t a solicitation for investment. Streetwise Reports does not leave specific or general investment advice and the advice on Streetwise Reports should not be thought of as a recommendation to buy or sell any security. Streetwise Reports doesn’t endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for interviews and articles on the website, may have a long or short position in securities mentioned. Directors, officers, employees or associates of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or from the time of their meeting or the decision to write a post prior to three business days after the publication of the interview or post. The foregoing prohibition does not apply to articles that in material simply restate previously published company releases.

EDGE is an artificial intelligence (AI) system that defines possible tumor neoantigens. It has shown an accuracy that is up to eight times greater than other forecast algorithms, such as MHCflurry and NetMHC.

Source: Streetwise Reports   03/09/2019
None of the study analysts or the research analyst’s household has a financial interest in the securities of Gritstone Oncology, Inc. and Advaxis, Inc. (including, without limitation, any option, right, justify, future, long or short position).
The research analyst primarily responsible for preparation of this report does not receive compensation that’s based upon some specific investment banking solutions or trade but is compensated based on variables such as overall revenue and sustainability of the Company, a significant part of which is derived from investment banking solutions.
As for revenue, H.C. Wainwright projects sales of vaccines to reach $6.5 billion by 2030, Ramakanth suggested. The market potential for GRANITE-001 could be much greater given it could turn into the very first vaccine for use for many cancer types. Together with the $20 million that bluebird bio Inc. (BLUE:NASDAQ) paid for it Gritstone could garner up to $1.2 billion in landmarks, constituting possible additional upside.

Initial clinical data should come this year. Gritstone is now evaluating GRANITE-001 in a Phase 1 research over four cancer forms in conjunction with checkpoint inhibitors: nonsmall cell lung, esophageal, pancreatic and kidney. Findings from this trial are expected in H2/19. “These results would provide an important first-look at how nicely Gritstone’s technological advantage in neoantigen identification and vaccine design is able to translate into clinical efficacy,” noted Ramakanth. If it might, “it could be a major catalyst for the inventory . ”

Subscribe to our FREE newsletter : www.streetwisereports.com/get-news
Disclosure:
Investment Banking Services include, but are not restricted to, acting as a manager/co-manager in the underwriting or placement of securities, or acting as financial adviser, or providing corporate fund or funds markets-related services to a business or among its affiliates or subsidiaries within the previous 12 months.
At a March 7 research note, analyst Swayampakula Ramakanth noted that H.C. Wainwright & Co. initiated coverage on Gritstone Oncology Inc. (GRTS:NASDAQ), a developer of neoantigen-targeting remedies for cancer, using a purchase and a $17 per share price target (versus the current share price of $10.93).
Ramakanth reviewed the firm ’s assets. Gritstone includes two cancer based on its proprietary EDGE technology, which can be GRANITE-001, also a “personalized heterologous prime/boost vaccine,” and SLATE-001, an embryo that is parasitic. Both “have the capability to be best-in-class therapies because of the superior precision of EDGE and the capability to get heterologous prime/boost vaccines to evoke stronger immune reactions compared to the homologous vaccines used by competitors,” Ramakanth commented.

Two Veins Discovered at Joint Venture’s Polymetallic Project in Mexico

Sourced from: https://www.countingpips.com/2019/03/two-veins-discovered-at-joint-ventures-polymetallic-project-in-mexico/

See what other pros are saying about:


Mineralization at the Venadas vein operates in a northeast direction and it is the first vein at the Fresnillo area to be oriented at a high angle to the mined northwest-running veins. Juanicipio is recognized to comprise larger northeast-oriented structures, not one of that has been explored so far. But with the Venadas vein discovery, they’ve become and now are priority targets.
( Firms Disclaimer: FRES:LSE,
Resource: Streetwise Reviews   03/07/2019

Subscribe to our FREE newsletter in: www.streetwisereports.com/get-news
MAG Silver Corp. (MAG:TSX; MAG:NYSE.MKT) announced in a news launch that results from the 48-hole, 46,060 meter (46,060m) diamond drill program in the Juanicipio project it co-owns using Fresnillo Plc (FRES:LSE) were optimistic and unearthed a new discovery.


“The Valdecañas strand system also has emerged as a multistage, high-grade vein swarm comprising the rectal East and West veins, the hanging wall Anticipada vein, the newly discovered Pre-Anticipada vein and lots of different splays,” the discharge noted.
By The Gold Report

Because of such drill results and the simple fact that the hole spacing in the deep corner is wide, MAG anticipates the Inferred category of Juanicipio tools to be affected the most.
The drill results not only confirmed section of the high level mineralization to depth but also expanded it at the East and West Valdecañas strand deep zones. The Deep zone West intersected 11.6m grading 783 g per bunch (783 g/t) silver and also 2.57 g/t gold at infill hole P22. The Deep zone East struck 6.3m grading 246 g/t silver and also 1.78 g/t gold from stepout hole P26.
Each the assays also contained lead, zinc and copper.
These geologic formations open new areas for mining on the house.
In another news launch issued the identical day, MAG Silver declared the mining group at Juanicipio found a new vein, also known as Venadas, which implies additional exploration potential there. The group members came upon it if they lined up 15 unconnected intercepts and subsequently confirmed it with drilling.

VEN-1, the very first drill hole targeting the Venadas strand, reduce 3m grading 392 g/t silver and 5.54 g/t gold. The base metals found were minimal in volume.

Exploration drilling continues at Juanicipio, as does growth of the surface and underground mines.

The aim of the campaign was to enlarge and infill the Deep zone nutrient resource estimate outlined at the preliminary financial assessment from 2017.
All intercepts are situated higher than 1,750m of elevation, with the majority of them “significantly higher” than 1,850m elevation, at which the top of this Valdecañas vein is situated. This suggests the Venadas vein has considerable thickness possible. “The cuts so far are at high elevations, therefore we are happy to drill them depth to find out if they improve like Valdecañas,” Chief Exploration Officer Dr. Peter Megaw stated in the launch.
Disclosure:
Members or her of her household own securities of these businesses mentioned in the article: None. Members or her of her household are compensated by these companies discussed in this article: Not one.
2) The following businesses discussed in this article are billboard sponsors of Streetwise Reports: MAG Silver. Click here for significant disclosures about host fees.
3) Comments and opinions expressed are those of their particular experts and not of Streetwise Reports or its officers. The information supplied above is for informational purposes only and isn’t a recommendation to buy or sell any security.
4) The content does not constitute investment advice. Every reader is invited to consult with their individual financial professional and any action a reader takes because of information presented here is his or her own duty. By opening this site, each reader agrees and accepts to Streetwise Reports’ terms of usage and complete authorized disclaimer. This article is not a solicitation for investment. Streetwise Reports doesn’t render general or specific investment information and the advice on Streetwise Reports shouldn’t be regarded as a recommendation to buy or sell any security. Streetwise Reports doesn’t support or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. Directors, officers, employees or members of the immediate families are prohibited from making purchases or earnings of those securities in the open market or from the time of the interview or the choice to compose an article until three business days following the publication of the interview or article. The foregoing prohibition doesn’t apply to posts that in substance just restate previously published firm releases.

The findings did exactly the same for the Anticipada vein. Highlight infill hole P24-1 revealed 6.2m grading 275 g/t silver and 4.02 g/t gold.
Unexpectedly, the results revealed that a vein not seen earlier , the Pre-Anticipada vein, located in the hanging wall over the geological system. There, stepout pit P28 revealed 3.2m grading 472 g/t silver and 0.31 g/t gold.

Gold Company to Start Exploration of Ecuadorian Acreage Using Financing Proceeds

Sourced from: https://www.countingpips.com/2019/03/gold-company-to-start-exploration-of-ecuadorian-acreage-using-financing-proceeds/

Disclosure:
)

The following Important Disclosures apply for Juggernaut Exploration:

Major Disclosures

Lundin Gold Inc. (LUG:TSX) will use the currencies from a recent funding to start exploring its 64,400-hectare gold house in Ecuador, as shown by a Haywood March 4 research note. “Commencement of mining activities on the company’s highly prospective land package should endure consequences, and we all look forward to the first meaningful exploration funding for quite a while,” analyst Kerry Smith documented.

As for the Fruita del Norte job, it stays on track for initial production by year-end 2019. Engineering function is 85% done, earthworks is 75% complete and power point structure is 27% completed. Procedure plant building continues to progress. “Gold prices are going higher, and timing is looking good for this new manufacturer to start production later this year,” noted Smith.
Haywood includes a Buy rating on Lundin Gold, along with a CA$7.50 per share target price, recently decreased from CA$7.75. The organization “will be a brand new producer with 290,000 ounce anticipated in 2020,” Smith wrote. Lundin Gold’s stock is currently trading at around CA$5.28 percent share, a great point for accumulating stocks the analyst added.
Lundin Gold’s bought-deal equity financing grossed CA$46.6 million in 8.625 million shares being issued at CA$5.40 per share, Smith indicated. These resources will be used “to fund exploration activities in addition to general corporate purposes. ” No significant exploration efforts have occurred on the property since the Fruita del Norte gold deposit was discovered.

1) Doresa Banning compiled this post for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the post: None. She or members of her family are compensated by the following companies discussed in this article: None.
2) The following businesses discussed in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about host fees.
3) Opinions and opinions expressed are those of their specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to talk to her or his individual financial professional and any actions a reader takes as a result of information presented here’s their own duty. By opening this site, every reader accepts and agrees to Streetwise Reports’ terms of usage and complete legal disclaimer. This guide is not a solicitation for investment. Streetwise Reports does not render general or specific investment information and the information on Streetwise Reports should not be considered a recommendation to purchase or sell any security. Streetwise Reports doesn’t endorse or recommend the company, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or members of their families, in addition to persons interviewed for interviews and articles on the website, might have a long or short position in securities mentioned. Directors, officers, employees or associates of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of their interview or the decision to compose a post until three business days following the publication of the interview or post. The foregoing prohibition does not apply to articles that in substance simply restate previously published company releases.

Source: Streetwise Reports   03/07/2019
The funding for mining at 2019 is roughly US$4approximately 6 million and also for 2020, US$10–12 million, “however, the applications will be results driven,” Smith clarified.
Smith emphasized that Lundin Gold’s fiscal picture, money balance plus debt, is enough to complete construction and take the Fruita del Norte mine through commissioning. Of those US$692 million capex budget for the project, US$372 million have been unused. At 2018, the firm had US$168 million in money.

This Canadian company ’s aims for the house are discussed at a Haywood report, which also provided an update on mine structure.
Representative Certification: ” , Kerry Smith, hereby certify that the views expressed within this report (which includes the evaluation assigned to the issuer’s shares in addition to the analytical substance and tone of the report) accurately reflect my/our personal views about the subject securities and the issuer’s. No portion of my/our compensation has been, is, or will be directly or indirectly related to the specific recommendations.
Research coverage can be found here.

( Companies Mentioned: LUG:TSX,

▪The Analyst(s) preparing this report (or a member of the Analysts’ families ) have a financial interest in Roxgold Inc..
Other material conflict of interest of this research analyst where the researcher or Haywood Securities Inc. knows or has reason to be aware in the time of publication or in the time of public look: n/a.

The Fruta del Norte job “ranks as one of the largest and highest-grade undeveloped gold projects on the planet,” Smith wrote.


Smith clarified that within the next two years, Lundin Gold will strategically and systematically explore the container for systems geologically like Fruita del Norte. It’ll drill high-priority targets pinpointed over the Suarez pull-apart container and run mapping and sampling to determine additional prospective targets.